Paraproteinemias clinical trials at UCSF
1 research study open to eligible people
Paraproteinemias are blood conditions where a single abnormal protein is made by plasma cells. UCSF is testing a new gene therapy for people with relapsed and refractory multiple myeloma. The study measures safety, tolerability, and the dose to use in later studies.
Showing trials for
Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
open to eligible people ages 18 years and up
The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.
San Francisco, California and other locations
Our lead scientists for Paraproteinemias research studies include Jodi Lipof, MD.
Last updated: